loading...| Preferred Name |
PEG-proline-interferon alpha-2b |
|
| Synonyms |
pegylated interferon alpha-2b |
|
| Definitions |
A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C111892" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C111892" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000753252 |
|
| altLabel |
pegylated interferon alpha-2b PEG-P-IFN-alfa-2b P1101 pegylated interferon alfa-2b PEG intron AOP2014 PEG-P-IFN-alpha-2b PEG interferon alpha-2b |
|
| cui |
C3888415 C3888416 C3827091 C1527737 C0796545 |
|
| DATE FIRST PUBLISHED |
2013-10-17 |
|
| Date last modified |
2015-12-16 |
|
| definition |
A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C111892" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C111892" NCI Thesaurus) |
|
| NCI ID |
C111892 |
|
| notation |
CDR0000753252 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
PEG-proline-interferon alpha-2b |
|
| tui |
T116 T129 T121 |